Human Brain Deuterium Metabolic Imaging at 7 T: Impact of Different 6,6′‐2H2Glucose Doses

Deuterium metabolic imaging (DMI) is an innovative, noninvasive metabolic MR imaging method conducted after administration of 2H-labeled substrates. DMI after 6,6'-2H2glucose consumption has been used to investigate brain metabolic processes, but the impact of different 6,6'-2H2glucose doses on DMI brain data is not well known. To investigate three different 6,6'-2H2glucose doses for DMI in the human brain at 7 T. Prospective. Six healthy participants (age: 28 ± 8 years, male/female: 3/3). 7 T, 3D 2H free-induction-decay (FID)-magnetic resonance spectroscopic imaging (MRSI) sequence. Three subjects received two different doses (0.25 g/kg, 0.50 g/kg or 0.75 g/kg body weight) of 6,6'-2H2glucose on two occasions and underwent consecutive 2H-MRSI scans for 120 minutes. Blood was sampled every 10 minutes during the scan, to determine plasma glucose levels and plasma 2H-Glucose atom percent excess (APE) (part-1). Three subjects underwent the same protocol once after receiving 0.50 g/kg 6,6'-2H2glucose (part-2). Mean plasma 2H-Glucose APE and glucose plasma concentrations were compared using one-way ANOVA. Brain 2H-Glc and brain 2H-Glx (part-1) were analyzed with a two-level Linear Mixed Model. In part-2, a General Linear Model was used to compare brain metabolite signals. Statistical significance was set at P < 0.05. Between 60 and 100 minutes after ingesting 6,6'-2H2glucose, plasma 2H-Glc APE did not differ between 0.50 g/kg and 0.75 g/kg doses (P = 0.961), but was significantly lower for 0.25 g/kg. Time and doses significantly affected brain 2H-Glucose levels (estimate ± standard error SE: 0.89 ± 0.01, 1.09 ± 0.01, and 1.27 ± 0.01, for 0.25 g/kg, 0.50 g/kg, and 0.75 g/kg, respectively) and brain 2H-Glutamate/Glutamine levels (estimate ± SE: 1.91 ± 0.03, 2.27 ± 0.03, and 2.46 ± 0.03, for 0.25 g/kg, 0.50 g/kg, and 0.75 g/kg, respectively). Plasma 2H-Glc APE, brain 2H-Glc, and brain 2H-Glx levels were comparable among subjects receiving 0.50 g/kg 6,6'-2H2glucose. Brain 2H-Glucose and brain 2H-Glutamate/Glutamine showed to be 6,6'-2H2glucose dose dependent. A dose of 0.50 g/kg demonstrated comparable, and well-detectable, 2H-Glucose and 2H-Glutamate/Glutamine signals in the brain. 1 TECHNICAL EFFICACY: Stage 2.